Financial Data and Key Metrics Changes - For Q4 2020, Axonics generated net revenue of $34.8 million, a significant increase from $9.9 million in Q4 2019 [23] - The net revenue from the United States accounted for $33.7 million, with certain European markets and Canada contributing the remainder [23] - Gross profit for Q4 2020 was $22.1 million, resulting in a gross margin of 63.6%, with expectations for gross margins to expand to the low to mid-70s in the coming years [24] - The net loss for Q4 2020 was $11.3 million, an improvement from a net loss of $22.8 million in Q4 2019 [25] - Cash and cash equivalents stood at $241.2 million as of December 31, 2020, with a pro forma cash balance of approximately $150 million after accounting for the Contura acquisition [25] Business Line Data and Key Metrics Changes - Axonics generated over $111 million in revenue during its first year of sales in the U.S., which was achieved in only 10 months [7] - The acquisition of Bulkamid is expected to be accretive to revenue growth, gross margins, and operating margins in 2021 and beyond [20] - Bulkamid generated approximately $11 million in sales in 2020, with a trajectory of approximately $15 million in annualized sales as of January 2021 [18] Market Data and Key Metrics Changes - The U.S. market for stress urinary incontinence (SUI) affects about 20 million women, with only a small fraction treated [9] - In the U.S., there are around 125,000 to 150,000 sling procedures annually, compared to approximately 25,000 bulking procedures [15] - Bulkamid has generated extensive clinical validation and a strong safety profile, with over 70,000 women treated to date [14] Company Strategy and Development Direction - The acquisition of Contura and its Bulkamid product line is seen as a strategic fit that enhances Axonics' value proposition in treating incontinence [10] - The company aims to leverage its existing sales force to accelerate Bulkamid's adoption, particularly in the U.S. [19] - Axonics is focused on expanding its commercial footprint and increasing awareness of Bulkamid among physicians [19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the recovery of elective procedures as COVID-19 vaccinations increase, expecting canceled cases to be rescheduled in the second half of 2021 [26] - The company is confident in its ability to meet or exceed the consensus revenue estimates for 2021, which is projected at around $157 million for the sacral neuromodulation business [51][68] - Management highlighted the strong demand for sacral neuromodulation and the positive reception from physicians and patients [27] Other Important Information - The FDA approved Bulkamid under PMA in early 2020, and it is reimbursed by Medicare and commercial payers in the U.S. [17] - The company has a detailed integration plan for Bulkamid, aiming for a smooth transition and operational synergy [21] Q&A Session Summary Question: Can you provide the history of Bulkamid's sales in Europe and its IP protection? - Management indicated confidence in the IP protection for Bulkamid and noted that the previous small organization had limited resources to grow sales [34][35] Question: What is the rationale behind the timing of the acquisition? - Management emphasized that the acquisition is an offensive strategy to enhance their market position and not a defensive move [56][57] Question: How is the company addressing the backlog of canceled procedures? - Management stated that they expect a steady uptick in procedures as COVID-19 cases decline and vaccinations increase, with Q4 expected to be the highest revenue quarter [66] Question: What is the expected revenue contribution from Bulkamid in 2021? - Management confirmed that Bulkamid's revenue would be additive to the core business, with expectations of generating approximately $50 million in revenue by 2024 [21][68]

Axonics Modulation Technologies, Inc. (NASDAQ:AXNX) Q3 2020 Earnings Conference Call November 4, 2020 4:30 PM ET Company Participants Neil Bhalodkar - Investor Relations Raymond Cohen - Chief Executive Officer Dan Dearen - President and Chief Financial Officer Conference Call Participants David Lewis - Morgan Stanley Bob Hopkins - Bank of America Chris Pasquale - Guggenheim Securities Adam Maeder - Piper Sandler Kaila Krum - Truist Securities Michael Polark - Baird Kevin Farshchi - Wells Fargo David Saxon - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________________________ FORM 10-Q _________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to _______ ...

Financial Data and Key Metrics Changes - Axonics generated net revenue of $15.2 million in Q2 2020, a significant increase from $1.5 million in Q2 2019 [13] - Gross profit for Q2 2020 was $6.8 million, resulting in a gross margin of 44.4%, which was lower than prior quarters due to COVID-19 related overhead absorption issues [13][14] - Net loss for Q2 2020 was $19.8 million, compared to a net loss of $19.1 million in Q2 2019 [15] - Cash and cash equivalents were approximately $288 million as of June 30, 2020, following a $140 million equity offering in early May [15] Business Line Data and Key Metrics Changes - U.S. revenue accounted for $14.6 million of the total revenue, with certain European markets and Canada contributing the remainder [13] - Axonics has seen a recovery in new order flow, reaching approximately 70% of the weekly average achieved in Q1 2020 by June [8] Market Data and Key Metrics Changes - The company reported that nearly 90% of patients trialed with their External Trial System were implanted with a permanent device, which is 10% to 15% higher than historical clinical literature [30] - Over 20% of implants to date have been associated with physicians replacing their InterStim devices with Axonics, indicating a strong trend in physician-driven conversions [31] Company Strategy and Development Direction - Axonics aims to become the global leader in sacral neuromodulation, focusing on innovation and improving patient experience [34] - The company is working on a long-lived, non-rechargeable device to expand its product line [33] - Axonics believes the sacral neuromodulation market is significantly underpenetrated and poised for growth, with expectations of market expansion in the coming years [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting or exceeding analysts' consensus estimates for the second half of 2020, despite challenges posed by COVID-19 [16] - The company noted that the recovery in outpatient elective procedures is contingent upon factors outside of their control, but they are well-positioned to take advantage of the demand for sacral neuromodulation [17] - Management highlighted positive feedback from physicians regarding the efficacy and ease of use of Axonics products, which is expected to drive further adoption [22] Other Important Information - Axonics received three significant FDA approvals in recent months, enhancing the patient experience and expanding the capabilities of their devices [9][10] - The company has signed over 135 corporate agreements with national and regional integrated delivery networks (IDNs) and large urology groups, allowing access to a broader market [33] Q&A Session Summary Question: Can you confirm the recovery tracking at around $3 million weekly revenue run rate prior to COVID-19? - Management indicated they are tracking close to that level [37] Question: Can you provide insights on the 540 unique centers and their contribution to implants? - Management confirmed the increase from 350 centers and noted that these centers are consistently reordering products [38][39] Question: What percentage of revenue in Q2 occurred in June, and how did July compare? - July was better than June, with a return to pre-pandemic order levels [48][49] Question: How is market share distributed among accounts? - Management noted that many accounts are fully committed to Axonics, with some still splitting business, but overall, they are seeing significant switching to Axonics [52][53] Question: Can you discuss the pace of recovery in July and August? - Management reported consistent order velocity throughout July and into early August, with no significant fluctuations [58] Question: What is the strategy regarding competition and bundling? - Management clarified that patients need either Axonics or Medtronic devices, and there is no bundling of products in sacral neuromodulation [59][60] Question: What is the timeline for the primary cell device filing? - Management confirmed plans to file the primary cell device with the FDA in early 2021 [62]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________________________ FORM 10-Q _________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ C ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________________________ FORM 10-Q _________________________________________________________________ (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ ...

Axonics Modulation Technologies, Inc. (NASDAQ:AXNX) Q4 2019 Earnings Conference Call March 4, 2020 4:30 PM ET Company Participants Neil Bhalodkar - VP of IR Raymond Cohen - CEO Dan Dearen - President and CFO Conference Call Participants David Lewis - Morgan Stanley Bob Hopkins - Bank of America Kristen Stewart - Barclays Larry Biegelsen - Wells Fargo Danielle Antalffy - SVB Leerink Kaila Krum - SunTrust Adam Maeder - Piper Sandler Operator Ladies and gentlemen, thank you for standing by and welcome to the A ...